Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Exact Sciences Corp (NASDAQ: EXAS) was $53.07 for the day, up 0.70% from the previous closing price of $52.70. In other words, the price has increased by $0.70 from its previous closing price. On the day, 2.58 million shares were traded. EXAS stock price reached its highest trading level at $54.06 during the session, while it also had its lowest trading level at $52.17.
Ratios:
Our analysis of EXAS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 99.79. For the most recent quarter (mrq), Quick Ratio is recorded 1.93 and its Current Ratio is at 2.12. In the meantime, Its Debt-to-Equity ratio is 0.87 whereas as Long-Term Debt/Eq ratio is at 0.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $75.
On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 13 ’24 when Conroy Kevin T bought 19,500 shares for $51.35 per share. The transaction valued at 1,001,325 led to the insider holds 1,074,191 shares of the business.
Baranick Brian sold 929 shares of EXAS for $65,030 on Oct 08 ’24. The EVP, GM, Precision Oncology now owns 12,758 shares after completing the transaction at $70.00 per share. On Oct 08 ’24, another insider, Baranick Brian, who serves as the Officer of the company, bought 929 shares for $70.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 9821983744 and an Enterprise Value of 11581961216. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.65 while its Price-to-Book (P/B) ratio in mrq is 3.06. Its current Enterprise Value per Revenue stands at 4.302 whereas that against EBITDA is -1021.607.
Stock Price History:
Over the past 52 weeks, EXAS has reached a high of $79.62, while it has fallen to a 52-week low of $40.62. The 50-Day Moving Average of the stock is -18.40%, while the 200-Day Moving Average is calculated to be -8.76%.
Shares Statistics:
EXAS traded an average of 2.59M shares per day over the past three months and 3742320 shares per day over the past ten days. A total of 185.08M shares are outstanding, with a floating share count of 182.38M. Insiders hold about 1.46% of the company’s shares, while institutions hold 99.79% stake in the company. Shares short for EXAS as of 1730332800 were 14059827 with a Short Ratio of 5.42, compared to 1727654400 on 14031981. Therefore, it implies a Short% of Shares Outstanding of 14059827 and a Short% of Float of 7.670000000000001.
